ITGB3 and Decreased total leukocyte count: All immune-modulator treatment groups displayed leukopenia in the lung vascular perfusate (p=0.0615; p<0.05 for anti-CD61 antibody) (Figure 1D) as well as peripheral blood (p=0.0201; p<0.05 for vehicle+ozone+LPS, anti-CD61 antibody, BTB06584 and propranolol) (Figure 1E) compartment, when compared to control group.